UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1365-6
Program Non-Formulary
Medication Zykadia® (ceritinib)*
P&T Approval Date 7/2021, 2/2022, 4/2022, 4/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic
lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by
an FDA-approved test. The National Cancer Comprehensive Network (NCCN) also recommends
Zykadia as first-line therapy for ALK-positive advanced or metastatic NSCLC, for the treatment
of inflammatory myofibroblastic tumor (IMT) with ALK translocation,in treatment of ALK-
positive brain metastases from NSCLC, in the treatment of ALK-positive Erdheim-Chester
Disease, advanced, recurrent, metastatic, or inoperable inflammatory myofibroblastic tumor
(IMT) with positive ALK translocation, and ALK-positive relapsed or refractory anaplastic large
cell lymphoma as palliative intent therapy or second-line and subsequent therapy.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Zykadia* will be approved based on the following criterion:
a. Member is less than 19 years of age
Authorization will be issued for 12 months.
B. Non-Small Cell Lung Cancer (NSCLC)
1. Initial Authorization
a. Zykadia* will be approved based on all of the following criteria:
(1) Diagnosis of non-small cell lung cancer (NSCLC)
-AND-
© 2025 UnitedHealthcare Services Inc.
1
(2) One of the following:
(a) Disease is metastatic
(b) Disease is recurrent
(c) Disease is advanced
-AND-
(3) Both of the following:
(a) Tumor is anaplastic lymphoma kinase (ALK)-positive
-AND-
(b) One of the following:
i. Provider attests the patient has a contraindication, history of intolerance,
or that the patient is not an appropriate candidate (document reason) to
all of the following therapies:
• Alecensa (alectinib)
• Alunbrig (brigatinib)
• Lorbrena (lorlatinib)
-OR-
ii. Both of the following:
• Patient is currently on Zykadia therapy
-AND-
• Patient has not received a manufacturer supplied sample at no cost
from a prescriber’s office, or any form of assistance from a Novartis
patient assistance program (e.g. sample card which can be redeemed
at a pharmacy for a free supply of medication) or a 30 day free trial
from a pharmacy as a means to establish as a current user of
Zykadia*
*Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from a Novartis patient assistance program shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Zykadia will be approved based on the following criterion:
© 2025 UnitedHealthcare Services Inc.
2
(1) Patient does not show evidence of progressive disease while on Zykadia therapy
Authorization will be issued for 12 months.
C. Soft Tissue Sarcoma
1. Initial Authorization
a. Zykadia will be approved based on the following criterion:
(1) Diagnosis of inflammatory myofibroblastic tumor (IMT) with ALK
translocation
Authorization will be issued for 12 months.
2. Reauthorization
a. Zykadia will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Zykadia therapy
Authorization will be issued for 12 months.
D. Central Nervous System (CNS) Cancers
1. Initial Authorization
a. Zykadia will be approved based on both of the following criteria:
(1) Diagnosis of metastatic brain cancer from NSCLC
-AND-
(2) Tumor is anaplastic lymphoma kinase (ALK)-positive
Authorization will be issued for 12 months.
2. Reauthorization
a. Zykadia will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Zykadia therapy
Authorization will be issued for 12 months.
E. Histiocytic Neoplasms
1. Initial Authorization
a. Zykadia will be approved based on all the following criteria:
© 2025 UnitedHealthcare Services Inc.
3
(1) Diagnosis of Erdheim-Chester Disease
-AND-
(2) Disease is positive for ALK rearrangement
Authorization will be issued for 12 months.
2. Reauthorization
a. Zykadia will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Zykadia
therapy.
Authorization will be issued for 12 months.
F. Anaplastic Large Cell Lymphoma
1. Initial Authorization
a. Zykadia will be approved based on all of the following criteria:
(1) Diagnosis of anaplastic large cell lymphoma
-AND-
(2) Tumor is anaplastic lymphoma kinase (ALK)-positive
-AND-
(3) Disease is relapsed or refractory
-AND-
(4) Used as palliative intent therapy or second-line and subsequent therapy
Authorization will be issued for 12 months.
2. Reauthorization
a. Zykadia will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Zykadia therapy
Authorization will be issued for 12 months.
G. NCCN Recommended Regimens
© 2025 UnitedHealthcare Services Inc.
4
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a Coverage of oncology medications may be approved based on state mandates.
* Zykadia is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer to
plan specifics to determine exclusion status.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Zykadia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October
2021.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
www.nccn.org. Accessed January 2, 2025
Program Non-Formulary - Zykadia (ceritinib)
Change Control
7/2021 New program.
2/2022 Removed “Prior Authorization” from program title and kept Non-
Formulary. Updated background and references. Added clinical
criteria for ROS1-positive or ALK-positive brain metastases from
NSCLC.
4/2022 Added oncology medications state mandate note.
4/2023 Annual review. Removed ROS-1 form CNS cancer as this is no longer
NCCN recommended. Added criteria for ALK-positive Erdheim-
Chester Disease per NCCN recommendations. Updated reference.
2/2024 Annual review. Updated background and coverage criteria for
inoperable inflammatory myofibroblastic tumor and anaplastic large
cell lymphoma per NCCN. Updated reference.
2/2025 Annual review. Removed ROS positive criteria from NSCLC as this is
no longer an NCCN recommendation. Removed criteria for IMT which
was duplicative as this is covered under soft tissue sarcomas. Updated
background and reference.
© 2025 UnitedHealthcare Services Inc.
5